Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging Markets Regulatory Tracker: Brazil (Vol. 4 No. 49)

This article was originally published in PharmAsia News

Executive Summary

Brazil publishes guidance on the implementation of its track and trace system for drugs.

The Emerging Markets Regulatory Tracker is prepared for PharmAsia News by RegLink Associates, which tracks regulatory, policy and health technology assessments around the world for biopharma and medical device executives.


Read all Breaking News from RegLink.

The previous issue of the Emerging Markets Regulatory Tracker appeared here: (Also see "Emerging Markets Regulatory Tracker: Australia (Vol. 4 No. 48)" - Scrip, 17 Aug, 2014.).

Track And Trace Implementation Guidance Issued

Brazil’s national regulatory agency, Anvisa, published guidance on Aug. 18 on the implementation of Brazil’s Track and Trace system for drugs, the National Drug Control System (SNCM). The guidance manual (IN) specifies the requirements for mandatory registration with SNCM, the data that should be made available to Anvisa, and the nature of the communication among participants within the pharmaceutical chain of distribution. The manual bas the subject of discussion within the Steering Committee for the Implementation of SNCM, which was established by ANVISA for tracking and monitoring the implementation of the national system. The Steering Committee has representation from 25 governmental agencies and other entities.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC087917

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel